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Abstract
Fourteen substances from the class of drugs sometimes known as “legal highs” were screened
against a battery of human receptors in binding assays, and their potencies as inhibitors of
monoamine uptake determined in functional in vitro assays. Thirteen of the test substances acted
as inhibitors of monoamine uptake at submicromolar concentrations, including 9 potent inhibitors
of the dopamine transporter (DAT), 12 potent inhibitors of the norepinephrine transporter (NET)
and 4 potent inhibitors of the serotonin transporter (SERT). Seven compounds acted as
submicromolar inhibitors of both DAT and NET, and three substances 1-(benzofuran-5-
yl)propan-2-amine (5-APB),1-naphthalen-2-yl-2-pyrrolidin-1-ylpentan-1-one hydrochloride,
(“naphyrone”) and 1-naphthalen-1-yl-2-pyrrolidin-1-ylpentan-1-one hydrochloride, (“1-
naphyrone”) were submicromolar inhibitors of all three monoamine transporters. There was a lack
of correlation between results of functional uptake experiments and in vitro binding assays for the
monoamine transporters. There was also no correlation between the human behavioural effects of
the substances and the results of bindings assays for a range of receptor targets, although 1-
(benzofuran-5-yl)propan-2-amine(5-APB), 1-(benzofuran-6-yl)propan-2-amine hydrochloride(6-
APB) and 5-iodo-2,3-dihydro-1H-inden-2-amine hydrochloride,(5-iodo-aminoindane) exhibited
<100nM affinities for 5HT2B and α2C receptors. Functional assays revealed that 5-APB and 6-
APB were potent full agonists at 5HT2B receptors.
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The recent emergence of novel synthetic psychoactive drugs and their sale through internet
sites has raised concerns about the potential harms associated with compounds for which
formal toxicology profiles are lacking (Corazzo et al, 2012; Winstock et al, 2011; ACMD,
2011). Among the novel psychoactive substances that have emerged in recent years are a
range of phenethylamine analogues designed to mimic the psychostimulant properties of
amphetamine and/or ecstasy (3,4-methylenedioxymethamphetamine, “MDMA”). These
include cathinone derivatives (e.g. mephedrone), aminoindanes, aminotetralins and
benzofurans (e.g. 1-(benzofuran-5-yl)propan-2-amine (5-APB) and 1-(benzofuran-6-
yl)propan-2-amine hydrochloride,(6-APB) –“benzo-fury”). The European Monitoring
Centre for Drugs and Drug Addiction (EMCDDA) monitors the emergence of these
psychoactive substances, reporting 42 new compounds during 2011 (EMCDDA Annual
Reports, 2010, 2011). These substances are sold without any safety data and have been
described as “plant food”, “bath salts”, “fish food” or simply as “research chemicals”. The
use of untested novel chemical substances presents clear potential hazards.
Pharmacologically, the psychostimulant actions of amphetamine and ecstasy are thought to
be related to their ability to promote the release of dopamine, norepinephrine and/or
serotonin from nerve terminals in the brain (Iversen, 2008). These drugs act not only as
competitive inhibitors of the respective monoamine transporters (DAT for dopamine), (NET
for norepinephrine) and (SERT for serotonin), but also as substrates for these uptake
systems acting to displace monoamines from their vesicular storage sites in the
synaptoplasm (Rothman and Baumann, 2003).
Studies of the pharmacological profiles of novel psychoactive compounds have revealed
their interactions with monoamine transporters. Nagai et al (2007) reported that a variety of
synthetic amphetamine and tryptamine analogues inhibited monoamine uptake and release
in rat brain synaptosomes. Simmler et al (2012) recently reported detailed studies on a range
of cathinone derivatives, showing many of them to be potent inhibitors of monoamine
transporters, using human targets, with a correlation between these properties and their
behavioural stimulant effects in vivo. Martinez-Clemente et al (2011) reported that
mephedrone inhibited dopamine and serotonin uptake in rat brain synaptosomes at
submicromolar concentrations, and had appreciable affinity for displacing selective DAT
and SERT radioligands in vitro. Mephedrone also had appreciable affinity for 5HT2 and
dopamine D2 receptors. Lopez-Arnau et al (2012) compared the neuropharmacological
profile of mephedrone with the related cathinones butylone and methylone, finding that all
three compounds inhibited monoamine uptake via DAT, NET and SERT. In addition
mephedrone had appreciable affinity for the vesicular monoamine transporter VMAT2
(Lopez-.Arnazu et al, 2012). In vivo the compounds also displayed amphetamine- and
MDMA-like behavioural stimulant activity in rats. Baumann et al (2012) and Kehr et al,
(2010) found that mephedrone and methylone increased the release of dopamine and
serotonin in rat brain using in vivo microdialysis techniques.
In the present study the resources of the National Institute of Mental Health Psychoactive
Drug Screening Program were used to obtain neurochemical profiles for 14 novel synthetic
psychoactive substances and to compare these profiles with those of amphetamine, MDMA
(‘ecstasy’), and other reference compounds. Unlike some previous studies, the present
results were largely obtained using human receptor and transporter targets.
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2. Materials and Methods
2.1 Chemicals
A sample of 2-methylamino-1-(4-methylphenyl)propan-1-one hydrochloride) “mephedrone”
was acquired from an internet supplier. The full spectral data and elemental analysis were
published (Gibbons and Zloh 2010) and were in close agreement with previously published
data (Camilleri et al., 2010).
The remaining thirteen chemicals were supplied as reference materials by LGC Standards,
as listed below:
1-(benzofuran-5-yl)propan-2-amine hydrochloride“5-APB”, “benzofury”
















Certified purities ranged from 95.2 to 99.9% (full Certificates of Analysis for each material
are available from the LGC Standards website, www.logical-standards.com).
Production of six of these reference materials (5-APB, 6-APB, benzedrone,
methylenedioxybenzedrone., 5-iodo-2-aminoindane and methiopropamine) was supported
by the UK’s Forensic Early Warning System (FEWS) and we thank the UK Home Office’s
Centre for Applied Science and Technology (CAST) for permission to use these materials in
this study.
2.2 Assays
Ki determinations, receptor binding profiles and functional assays were provided by the
National Institute of Mental Health’s Psychoactive Drug Screening Program essentially as
previously described (Roth et al, 2002; Setola et al, 2003; Zolkowska et al, 2009; Jensen et
al, 2008). A total of 14 compounds (mephedrone, methiopropamine, methylenedioxy-N-
benzylcathinone, 5-APB, 6-APB, 5-Iodo-aminoindane, benzedrone, desoxypipradrol,
dimethylamylamine, methylenedioxyaminotetralin, methylenedioxyaminoindane, 1-
naphyrone, naphyrone and methylethcathinone) were screened against a total of 49
molecular targets listed in Table 1 initially in quadruplicate at 10 μM concentration (N=686
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screening assays). Compounds which yielded inhibition of binding > 50% were subjected to
Ki determinations via 12-point concentration-response studies in triplicate as described
previously (Jensen et al, 2008). Functional assays of potencies of compounds as inhibitors of
monoamine uptake at human cloned transporters were determined using the Molecular
Devices Neurotransmitter Assay Kit (NET = norepinephrine transporter; DAT = dopamine
transporter; SERT = serotonin transporter). h5-HT 2B serotonin receptor functional assays
were performed as described using a FLIPRTETRA in the 384-well format (Jensen et al,
2008).
3. Results
In keeping with the amphetamine/MDMA-like profiles of these compounds as subjectively
reported by human users thirteen of the fourteen compounds tested were active at
submicromolar concentrations as inhibitors of substrate uptake by at least one monoamine
transporter (the exception being benzedrone – NET Ki = 1222 nM; DAT Ki = 1411 nM)
(Table 2). Overall the compounds were more potent inhibitors of NET and DAT than of
SERT. Seven compounds were active at submicromolar concentrations on DAT and NET;
nine were active at submicromolar concentrations on DAT, and twelve were active at
submicromolar concentrations on NET. Only three compounds (5-APB, 5-iodo-aminoindane
and naphyrone) acted as submicromolar inhibitors of SERT. Some of the most potent
inhibitors had Ki values <100nM for DAT inhibition (desoxypipradrol, naphyrone and 1-
naphyrone).
Screening of the test compounds on a range of neurotransmitter receptors revealed various
submicromolar affinity interactions, but unlike the data for monoamine uptake, the pattern
of activity did not correlate with the psychostimulant actions of these substances (Fig 1 and
Supplementary Tables 1–6). Some notably high affinity interactions were observed at 5-
HT2B serotonin receptors for 5-APB (Ki = 14nM) and 6-APB (Ki = 3.7nM), and 5-iodo-
aminoindane (Ki = 70nM) (Supplemental Table 2). Functional assays confirmed that 5-APB
and 6-APB were potent full agonists at human 5-HT2B serotonin receptors (Figure 2).
Furthermore, 6-APB and 5-iodo-aminoindane exhibited high affinities (Ki values of 45nM
and 89nM respectively) for α2C adrenoceptors (Supplementary Table 3). Submicromolar
affinities were seen for some compounds at various histaminergic and muscarinic receptors
as well as at σ1 and σ2 binding sites. No assayed compound had appreciable affinities for
any of the following receptors: GABA-A or GABA-B orthosteric binding sites, central or
peripheral benzodiazepine receptors, CB1 or CB2 cannabinoid receptors, NMDA receptors
(MK801 site) or any of the other targets in the screen(Supplementary Tables 4-6).
4. Discussion
4.1
The present study confirms and extends previous reports regarding the relatively potent
actions of novel psychostimulants on monoamine transporters. Previous studies have
focused on cathinone derivatives (Setola et al, 2003; Simmler et al, 2012) including the most
widely used drugs, mephedrone and methylone (Martinez-Clements et al 2012; López-
Arnau et al, 2012; Baumann et al, 2012), the latter using rat tissue preparations as sources of
molecular targets. As the synthetic drugs were designed to mimic the actions of
amphetamine and/or MDMA these results are not particularly surprising. The potencies of
several of the synthetic drugs tested were comparable to or greater than the reference
compounds d-amphetamine, MDMA and cocaine (Supplementary Table 2). Some test
compounds resembled MDMA in acting as submicromolar inhibitors of all three monoamine
transporters (Supplementary Table 2). While there is no direct correlation between the
subjective effects of any particular compound and inhibition of one or other monoamine
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transporter, this property is considered key. Twelve of the fourteen drugs tested acted as
submicromolar inhibitors of norepinephrine uptake (NET). This can explain the common
occurrence of sympathomimetic effects of these drugs on the cardiovascular system (Regan
et al 2010; Wood et al, 2010). Inhibition of norepinephrine uptake in brain may also
contribute importantly to the psychostimulant effects of these drugs. Administration of the
selective NET inhibitor reboxetine to human subjects reduced the effects of MDMA in
increasing blood pressure and heart rate and also reduced the subjective drug high, including
stimulation and emotional excitation (Hysek et al., 2011).
There was a weak correlation between the Ki values from functional assays (i.e., inhibition
of substrate uptake) and from binding assays (i.e., inhibition of radioligand binding) for the
transporter proteins, although six compounds had submicromolar Ki values for at least one
or other transporter radioligand binding sites (Table 2). Notably high affinities (<100nM)
were found for methylenedioxybenzedrone- and 5-APB at DAT, naphyrone and 1-
naphyrone at SERT, and naphyrone at NET. The poor correlation probably reflects the fact
that transporter inhibitors are likely to bind to different sites on the transporter than the
radioligands used for displacement assays, and the fact that transporter substrate uptake
assays were not performed at equilibrium. These results also suggest that functional
measurement of drug effects on substrate reuptake may be the most reliable method of
assessing drug effects on monoamine transporters. The present study included some
cathinone derivatives already reported to be monoamine transport inhibitors (Martinez-
Clemente et al, 2011; Lopez-Arnou et al, 2012; Simmler et al, 2012) – there was a good
overall agreement between the current data and these findings.
In addition to their effects on monoamine transporters, screening of the drugs against a wide
battery of human receptors and other CNS targets revealed a variety of other potentially
significant interactions. Although among these interactions were several with
submicromolar potency, there was no common target shared by all or most of the fourteen
tested compounds.
Interactions with serotonin receptors could be particularly important, since modulation of
serotoninergic transmission by drugs of abuse may underlie addiction vulnerability (Kirby et
al, 2011). Some notable high affinity interactions were observed between 5-HT2B receptors
for 5-APB (Ki =14nM) and 6-APB(Ki = 3.7nM), and 5-iodo-aminoindane (Ki = 70nM).
Functional assays of 5-APB and 6-APB confirmed that these compounds acted as potent
(i.e., nanomolar EC50 values) full agonists at 5-HT2B receptors (Figure 2). Four other
compounds exhibited submicromolar affinities for the 5-HT2B receptor (mephedrone,
naphyrone, 1-naphyrone and methylenedioxy-aminotetralin). This finding is potentially
important because previous studies have shown that there was a correlation in a series of
phenyl isopropylamines between hallucinogenic activity and affinity for the 5-HT2B
receptor (Nelson et al, 1999), and activation of this receptor appears to play a key role in the
behavioural stimulant and serotonin releasing effects of MDMA (Doly, 2008) and in the
reinforcing effects of MDMA in mice (Doly et al 2009). The activation of 5-HT2B receptors
by MDMA induces fenfluramine-like proliferation of cardiac valvular interstitial cells
(Setola et al, 2003; Roth, 2007), and the drug was linked to increased prevalence of valvular
heart disease in a group of Belgian MDMA users (Droogmans et al 2007). Indeed all drugs
and drug metabolites that induce heart valvular disease in humans activate 5-HT2B receptors
in vivo and in vitro and this activity is thought to be important for the development of
fibrotic lesions upon chronic human administration (Huang et al 2009; Elengbam, 2010;
Elengbam et al 2008; Roth, 2007). Therefore the finding that some of the compounds were
as potent or more potent 5-HT2B receptor agonists than MDMA suggests the risk of
potential cardiac toxicity with long term use) as has been reported for other 5-HT2B receptor
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agonists, including fenfluramine (Rothman et al, 2000), pergolide, cabergoline and MDMA
(for review see Roth 2007 and Berger et al, 2009).
6-APB and 5-iodo-aminoindane also had high affinities (Ki’s 45nM and 89nM respectively)
for α2C adrenoceptors although the significance of this is currently unknown.
4.2
In summary, we evaluated the molecular pharmacology of 14 novel psychoactive
compounds and discovered that many of them had relatively potent activities as biogenic
amine transporter antagonists—similar to the widely abused drugs cocaine, amphetamine
and MDMA. As might be expected from the diversity of chemical structures, a variety of
‘off-target’ actions at miscellaneous CNS targets was also discovered. Notably, several
compounds were potent 5-HT2B serotonin receptor agonists, raising the possibility that long-
term abuse of these compounds could be associated with valvular heart disease similar to
that induced by fenfluramine, MDMA and various ergolines.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Radioligand binding profile of novel psychoactive compounds
Shown is a three dimensional plot of mean pKi values of the 14 novel psychoactive
compounds screened against 49 distinct molecular targets (see Supplementary Tables for
mean +/− SEM data). Abbreviations are as in Table 1 except: BZP rat brain site=rat brain
benzodiazepine receptor; PBR=peripheral benzodiazepine receptor. See Supplementary
Table 6 for pIC50 values
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Figure 2. Potent 5-HT2B agonist activity of 5- and 6-APB
Shown are concentration-response curves for 5- and 6-APB as well as 5-HT (control) –
induced mobilization of intracellular Ca++ release at human cloned 5-HT2B receptor
expressed in HEK-T cells. Data represent mean +/− S.E.M of triplicate determinations;
where no error bar is shown the error was smaller than the bar. The data in the table
represent computer-derived estimates from N of at least 3 separate experiments +/− S.E.M.
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Table 1
Primary and Secondary Radioligand Binding Assays
Serotonin Receptors 5-HT1A, 5-HT1B, 5-HT1D, 5-HT1E, 5-HT2A, 5-HT2B, 5-HT2C, 5-HT3, 5-HT5A, 5-HT6, 5-HT7
Dopamine Receptors D1, D2, D3, D4, D5
Glutamate Receptors rNMDA Receptor (MK-801 binding site), mGluR5
GABA Receptors rGABA-A, rGABA-B, central and peripheral benzodiazepine sites
Biogenic Amine Transporters SERT, NET, DAT
Adrenoceptors α2A, α2B, α2C. β1, β2, β3, α1A, α1B, α1Δ
Cannibinoid CB1, CB2
Muscarinic Receptors M1, M2, M3, M4, M5
Opioid Receptors MOR, KOR, DOR
Sigma Receptors rSigma1, rSigma2
Histamine Receptors H1, H2, H3, H4
Shown are the human cloned neurotransmitter receptors, ion channels and transporters assayed in this study except where noted; r=Rat
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Table 2
Effects of novel psychoactive compounds on serotonin (SERT), dopamine(DAT) and norepinephrine (NET)
transporter activity.
Compound NET DAT SERT
Mephedrone 5.88±0.07 (511) 6.08±0.07 (543) 4.99±0.06 (4943)
Methiopropamine 6.09±0.07 (313) 6.05±0.07 (577) 4.14±0.07 (>10000)
Methylenedioxy-N-benzylcathinone 5.37±0.07 (1629) 6.01±0.07 (637) 4.53±0.06 (>10000)
5-APB 6.33±0.07 (180) 6.30±0.07 (265) 5.78±0.06 (811)
6-APB 6.52±0.07 (117) 6.63±0.07 (150) 5.26±0.06 (2698)
Desoxypipradrol 6.26±0.07 (213) 7.30±0.06 (32) 4.27±0.07 (>10000)
5-iod-2-aminoindane 6.09±0.07 (311) 5.61±0.06 (1590) 5.75±0.06 (879)
Benzedrone 5.50±0.07 (1222) 5.64±0.06 (1491) 4.75±0.06 (>10000)
Dimethylamylamine 5.77±0.07 (649) 4.74±0.06 (>10000) 3.75±0.13 (>10000)
Methylenedioxy-aminoindane 5.78±0.07 (641) 5.12±0.06 (4924) 4.93±0.06 (>10000)
Methylenedioxy-aminotetralin 5.64±0.07 (894) 5.20±0.06 (4067) 5.65±0.06 (1104)
Naphyrone 6.70±0.07 (200) 7.28±0.06 (53) 6.63±0.06 (235)
1-Naphyrone 6.27±0.07 (536) 7.32±0.06 (48) 6.45±0.06 (352)
Methylethcathinone 5.36±0.07 (1668) 6.08±0.06 (565) 5.43±0.06 (1798)
Amitriptyline* 6.14±0.07 (178) 5.01±0.08 (4638) 6.80±0.06 (123)
Nomifensine* 7.04±0.07 (26) 6.90±0.06 (66) 5.56±0.06 (4731)
Cocaine* 5.20±0.10 (1275) 6.19±0.06 (249) 5.62±0.08 (818)
(−)-MDMA* 5.50±0.10 (704) 5.21±0.06 (2425) 5.17±0.,08 (2306)
(+)-MDMA* 5.70±0.10 (398) 5.62±0.06 (897) 5.56±0.08 (948)
(+)-Amphetamine* 6.20±0.10 (101) 6.54±0.05 (109) 4.78±0.09 (5728)
Fluoxetine* 5.20±0.10 (1394) 5.04±0.06 (3764) 6.55±0.08 (98)
Data represent mean pKi +/− S.E.M (N =3) and Ki in nM for inhibitory potencies of various novel psychoactive compounds with comparator data
for psychostimulants and antidepressants. Values for comparator compounds (marked *) were obtained from assays performed at the same time as
test compounds. Samples of the comparator compounds were obtained from the NIMH-PDSP. Ki values highlighted in bold type indicate the most
potent interactions (Ki < 100 nM).
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